Ab Science

Beth Israel Deaconess Medical Center, Inc.

Heska Corporation

Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-hopitaux De Paris

Universite Paris Cité

Imagine Institut Des Maladies Genetiques Necker Enfants Malades

Quercegen Pharma LLC

Jean-Pierre Kinet

Alain Moussy

Tony Fleming

Marie-Helene Jouvin

Bruno Giethlen

Yukio Sudo

Camille Georges Wermuth

Olivier Hermine

Marco Ciufolini

Yuan Liu

Y-s Edmond Cheng

Caroline Carvalho

Slimane Allali

David Piquemal

Rachel Rignault-bricard

Colin Mansfield

Xiuqi Qian

John Chu

Thiago Trovati Maciel

A 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of sickle cell disease in a patient in need thereof. Also, a 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the prevention and/or treatment of acute chest syndrome (ACS) in a sickle cell disease patient in need thereof.

Masitinib for the treatment of sickle cell disease

A method for treating patients afflicted with cancer, wherein the patients are treated with a compound including tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one antineoplastic agent. The tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, and the optional at least one antineoplastic agent, are administered in a dosage regimen that includes a therapeutically effective amount. Also described are methods for predicting therapeutic response to the treatment in a given patient and therefore identification of applicable patient subpopulations based upon these predictor factors; sometimes referred to as biomarkers. One method is based upon the clinical marker of pain intensity. Another method is based upon gene expression predictive biomarkers assessed via RNA expression in peripheral blood cell samples collected prior to treatment with the compound, which is also used for treating patients afflicted with pancreatic cancer.

Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors

Disclosed is a method for treating patients afflicted with non-aggressive or moderately aggressive amyotrophic lateral sclerosis (ALS) whose rate of change of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) prior to treatment initiation is &#x3c;1.1 points per month, the method including administering a tyrosine kinase inhibitor or mast cell inhibitor, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.

Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation

The treatment of mastocytosis, and in particular indolent forms of mastocytosis (including smoldering systemic, indolent systemic and cutaneous mastocytosis), including the administration of a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt or solvate thereof, in particular in an appropriate dosage regimen.

Treatment of mastocytosis with masitinib

The present invention relates to the treatment of severe persistent asthma, and in particular severe persistent corticosteroid-dependent or corticosteroid-resistant asthma, comprising administration a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt thereof.

Treatment of severe persistant asthma with masitinib

The present invention relates to a tyrosine kinase inhibitor or a mast cell inhibitor, and in particular masitinib or a pharmaceutically acceptable salt thereof, for the treatment of human multiple sclerosis.

Treatment of multiple sclerosis with masitinib

The present invention relates to the use of masitinib or a pharmaceutically acceptable salt thereof, and in particular of masitinib mesylate, for the preparation of a medicament for the treatment of GIST, to the use of this therapy for the treatment of GIST, and a method of treating mammals, including humans, suffering from GIST by administering to said mammal in need of such treatment an effective dose of masitinib, and in particular masitinib mesylate.

2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors

The present invention relates to a method for treating solid cancers including non-small 5 cell lung cancer, pancreatic, bladder, breast and ovarian cancer as well as advanced biliary tract cancers comprising administering at least one antineoplasticagent such as a nucleotide analog, for example gemcitabine, or an antimitotic such as docetaxel, in combination with a tyrosine kinase inhibitor selected from 2-aminoarylthiazoles and 2-aminoaryloxazoles.

Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors

Humanized monoclonal antibodies against the vaccinia virus B5R surface antigen. The antibodies are effective in treating smallpox infection. Also disclosed are nucleic acids that encode the heavy and light chains of such antibodies and cells that express them.

Smallpox monoclonal antibody

The present invention relates to a method for treating allergic diseases such as asthma, comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

Use of tyrosine kinase inhibitors for treating allergic diseases

The present invention relates to a method for treating inflammatory bowel diseases (IBD), such as crohn's disease, comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)

Calcium independent CD81 inhibition of IgE-mediated degranulation in mast cells, particularly through the Fc&#x3b3;RIII and Fc&#x3b5;RI receptors, is described, as well as methods of inhibiting allergic processes.

Calcium-independent negative regulation by CD81 of receptor signalling

Calcium independent CD81 inhibition of IgE-mediated degranulation in mast cells, particularly through the Fc&ggr;RIII and FC&egr;RI receptors, is described, as well as methods of inhibiting allergic processes.

Calcium-independent negative regulation by CD81 of receptor signaling

The present invention includes a method to detect chronic pulmonary diseases of the airways associated with anti-Fc.sub..epsilon. R IgG autoantibodies. Preferred diseases to detect include atopic asthma and non-atopic asthma. The invention also includes methods to prescribe and monitor treatment for animals with such diseases. Also included are kits to detect disease as well as kits to prescribe or monitor treatment. The present invention also includes formulations to treat chronic pulmonary diseases of the airways associated with anti-Fc.sub..epsilon. R IgG autoantibodies. Preferred formulations include compounds that inhibit the ability of anti-Fc.sub..epsilon. R IgG autoantibodies in susceptible animals to bind to Fc.sub..epsilon. R-expressing cells. Also included are methods to treat such diseases.

Detection of anti-Fc.sub..epsilon. R autoantibodies in asthmatics

Disclosed are chemical agents with unexpected activity to inhibit the interactions between human immunoglobulin E (IgE) and its receptor (Fc.epsilon.RI) which interactions are known to be involved in triggering allergic responses. The agents may be used to module the allergic response in the treatment of various clinical conditions, including rhinitis, asthma, urticaria, atopic dermatitis, and anaphylacric shock. The agents can be formulated for oral, topical or parenteral administration.

Growing community of inventors

Lexington, MA, United States of America

Jean-Pierre Kinet